Hutchmed registers first-in-human Phase I/IIa trial of HMPL-A830 in solid tumors
New trial for HMPL-A830 has been posted to ClinicalTrials.gov; the study is not yet recruiting and is estimated to start in August 2026.
This week brought one registry update for Hutchmed, a newly listed early-phase oncology trial.
- HMPL-A830, a drug being tested in adults with advanced or metastatic solid tumors, has a new Phase I/IIa trial registered under NCT07718581, with an overall status of not yet recruiting. The study is a first-in-human, multicenter, open-label study for participants with unresectable, advanced, or metastatic solid tumors who are refractory or have progressed on standard treatment.1 The trial plans a Dose Escalation Part A enrolling approximately 57 participants, followed by a Dose Optimization Part B enrolling approximately 90 participants,1 for a total estimated enrollment of 147. Primary completion is estimated for June 26, 2028.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.